Nanobiotix S.A. (EPA:NANO)
3.244
-0.056 (-1.70%)
Apr 1, 2025, 12:42 PM CET
Nanobiotix Employees
Nanobiotix had 102 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€383,673
Profits / Employee
€304,300
Market Cap
156.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sanofi | 82,878 |
EssilorLuxottica Société anonyme | 153,498 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 13,982 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 5,459 |
emeis Société anonyme | 77,954 |
Nanobiotix News
- 1 day ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 4 days ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 11 days ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 13 days ago - Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden - Benzinga
- 14 days ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire
- 6 weeks ago - Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares - GuruFocus
- 2 months ago - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - GlobeNewsWire